IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0220605.html
   My bibliography  Save this article

Gap analysis for drug development policy-making: An attempt to close the gap between policy and its implementation

Author

Listed:
  • Ria Christine Siagian
  • Dumilah Ayuningtyas

Abstract

Introduction: Most drug development policies in developing countries are enacted without achieving the desired results. This study aims to determine the prioritization of drug development in Indonesia through the evidence-based policymaking process in order to close the distance between stated policy goals and the realization of planned goals. Methods: A quantitative approach in the form of cross-sectional research using a structured survey was adopted and validated using a set of techniques involved in the calculation of a structural equation model. An independent samples t-test was used to test the significance of the differences between two views: pharmaceutical industries and the government of Indonesia. Findings: The study reveals that pharmaceutical industries and governments were highly consistent in their perceived challenges in facing the drug development. It also reveals drivers and weaknesses of drug development, including market opportunities, push-pull-regulatory pull factors and regulation, as priorities for improvement. Conclusions: Gap analysis based on a structural model was borne out to address gap challenges between policy and its implementation, with the use of evidence-based policymaking.

Suggested Citation

  • Ria Christine Siagian & Dumilah Ayuningtyas, 2019. "Gap analysis for drug development policy-making: An attempt to close the gap between policy and its implementation," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-13, August.
  • Handle: RePEc:plo:pone00:0220605
    DOI: 10.1371/journal.pone.0220605
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0220605
    Download Restriction: no

    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0220605&type=printable
    Download Restriction: no

    File URL: https://libkey.io/10.1371/journal.pone.0220605?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Bahr Weiss & Amie Alley Pollack, 2017. "Barriers to global health development: An international quantitative survey," PLOS ONE, Public Library of Science, vol. 12(10), pages 1-23, October.
    2. Marco Liverani & Benjamin Hawkins & Justin O Parkhurst, 2013. "Political and Institutional Influences on the Use of Evidence in Public Health Policy. A Systematic Review," PLOS ONE, Public Library of Science, vol. 8(10), pages 1-9, October.
    3. Morgan, Steve & Grootendorst, Paul & Lexchin, Joel & Cunningham, Colleen & Greyson, Devon, 2011. "The cost of drug development: A systematic review," Health Policy, Elsevier, vol. 100(1), pages 4-17, April.
    4. Todd Gammie & Christine Y Lu & Zaheer Ud-Din Babar, 2015. "Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries," PLOS ONE, Public Library of Science, vol. 10(10), pages 1-24, October.
    5. Vincent Ahonkhai & Samuel F Martins & Alexandre Portet & Murray Lumpkin & Dan Hartman, 2016. "Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization," PLOS ONE, Public Library of Science, vol. 11(11), pages 1-12, November.
    6. Mueller-Langer, Frank, 2013. "Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research?," Health Economics, Policy and Law, Cambridge University Press, vol. 8(2), pages 185-208, April.
    7. Maryam Bigdeli & Shamsa Zafar & Hafeez Assad & Adbul Ghaffar, 2013. "Health System Barriers to Access and Use of Magnesium Sulfate for Women with Severe Pre-Eclampsia and Eclampsia in Pakistan: Evidence for Policy and Practice," PLOS ONE, Public Library of Science, vol. 8(3), pages 1-9, March.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Shiyong Wu & Wenxin Chen & Wei Chen & Wen Zheng, 2022. "Effects of Cultural Intelligence and Imposter Syndrome on School Belonging through Academic Resilience among University Students with Vocational Backgrounds," IJERPH, MDPI, vol. 19(13), pages 1-16, June.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. G. Kent Fellows & Daniel J. Dutton & Aidan Hollis, 2018. "Making Sure Orphan Drugs Don’t Get Left Behind," SPP Communique, The School of Public Policy, University of Calgary, vol. 10(6), August.
    2. Nicholas Bagley & Benjamin Berger & Amitabh Chandra & Craig Garthwaite & Ariel D. Stern, 2018. "The Orphan Drug Act at 35: Observations and an Outlook for the Twenty-First Century," NBER Chapters, in: Innovation Policy and the Economy, Volume 19, pages 97-137, National Bureau of Economic Research, Inc.
    3. Makai, Peter & Brouwer, Werner B.F. & Koopmanschap, Marc A. & Stolk, Elly A. & Nieboer, Anna P., 2014. "Quality of life instruments for economic evaluations in health and social care for older people: A systematic review," Social Science & Medicine, Elsevier, vol. 102(C), pages 83-93.
    4. Jason C Hsu & Huai-Chueh Wu & Wen-Chia Feng & Chih-Ho Chou & Edward Chia-Cheng Lai & Christine Y Lu, 2018. "Disease and economic burden for rare diseases in Taiwan: A longitudinal study using Taiwan’s National Health Insurance Research Database," PLOS ONE, Public Library of Science, vol. 13(9), pages 1-14, September.
    5. Padmashree Gehl Sampath, 2022. "Strade Measures On Pharmaceutical Products: Can They Promote Local Production And Public Health?," Asia-Pacific Sustainable Development Journal, United Nations Economic and Social Commission for Asia and the Pacific (ESCAP), vol. 29(2), pages 47-69, November.
    6. Shiwei Gong & Dehe Li & Dong Dong, 2020. "How Do Patients and Doctors Perceive Medical Services for Rare Diseases Differently in China? Insights from Two National Surveys," IJERPH, MDPI, vol. 17(16), pages 1-14, August.
    7. Norah L. Crossnohere & Ryan Fischer & Andrew Lloyd & Lisa A. Prosser & John F. P. Bridges, 2021. "Assessing the Appropriateness of the EQ-5D for Duchenne Muscular Dystrophy: A Patient-Centered Study," Medical Decision Making, , vol. 41(2), pages 209-221, February.
    8. Pereira, Cristiano Gonçalves & Lavoie, Joao Ricardo & Garces, Edwin & Basso, Fernanda & Dabić, Marina & Porto, Geciane Silveira & Daim, Tugrul, 2019. "Forecasting of emerging therapeutic monoclonal antibodies patents based on a decision model," Technological Forecasting and Social Change, Elsevier, vol. 139(C), pages 185-199.
    9. Adrian Towse;Jimena Ferraro;Jorge Mestre-Ferrandiz, 2017. "Incentives for New Drugs to Tackle Anti-Microbial Resistance," Briefing 001842, Office of Health Economics.
    10. Dyfrig A Hughes & Jannine Poletti-Hughes, 2016. "Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control Study," PLOS ONE, Public Library of Science, vol. 11(10), pages 1-12, October.
    11. Béné, Christophe, 2022. "Why the Great Food Transformation may not happen – A deep-dive into our food systems’ political economy, controversies and politics of evidence," World Development, Elsevier, vol. 154(C).
    12. Chen, Xu & Yang, Huan & Wang, Xiaojun, 2019. "Effects of price cap regulation on the pharmaceutical supply chain," Journal of Business Research, Elsevier, vol. 97(C), pages 281-290.
    13. Anita Chawla & Ginger Carls & Edmund Deng & Edward Tuttle, 2015. "The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation," PharmacoEconomics, Springer, vol. 33(7), pages 749-763, July.
    14. Cyr, Pascale Renée & Jain, Vageesh & Chalkidou, Kalipso & Ottersen, Trygve & Gopinathan, Unni, 2021. "Evaluations of public health interventions produced by health technology assessment agencies: A mapping review and analysis by type and evidence content," Health Policy, Elsevier, vol. 125(8), pages 1054-1064.
    15. Jimmy Le, 2014. "Financing Sustainable Drug Development for Neglected Diseases: A Case of Push-Pull Mechanisms and Global Public Goods," The Economic and Social Review, Economic and Social Studies, vol. 45(2), pages 245-259.
    16. Ryan Petteway & Mahasin Mujahid & Amani Allen & Rachel Morello-Frosch, 2019. "Towards a People’s Social Epidemiology: Envisioning a More Inclusive and Equitable Future for Social Epi Research and Practice in the 21st Century," IJERPH, MDPI, vol. 16(20), pages 1-21, October.
    17. Samira Guennif, 2022. "Capture and passive predation in times of COVID-19 pandemic," Public Choice, Springer, vol. 193(3), pages 163-186, December.
    18. Erik Landfeldt & Josefin Edström & Cecilia Jimenez-Moreno & Baziel G. M. Engelen & Janbernd Kirschner & Hanns Lochmüller, 2019. "Health-Related Quality of Life in Patients with Adult-Onset Myotonic Dystrophy Type 1: A Systematic Review," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 12(4), pages 365-373, August.
    19. Degtiar, Irina, 2017. "A review of international coverage and pricing strategies for personalized medicine and orphan drugs," Health Policy, Elsevier, vol. 121(12), pages 1240-1248.
    20. van Rijnsoever, Frank J. & Eveleens, Chris P., 2021. "Money Don't matter? How incubation experience affects start-up entrepreneurs' resource valuation," Technovation, Elsevier, vol. 106(C).

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0220605. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.